INQOVI Drug Patent Profile

Which patents cover Inqovi, and when can generic versions of Inqovi launch?

Inqovi is a drug marketed by Taiho Oncology and is included in one NDA. There are six patents protecting this drug.

This drug has ninety-three patent family members in forty-one countries.

The generic ingredient in INQOVI is cedazuridine; decitabine. One supplier is listed for this compound. Additional details are available on the cedazuridine; decitabine profile page.

DrugPatentWatch^® Generic Entry Outlook for Inqovi

Inqovi was eligible for patent challenges on July 7, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 22, 2030. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for INQOVI

International Patents:	93
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	15
Clinical Trials:	28
Drug Prices:	Drug price information for INQOVI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INQOVI
What excipients (inactive ingredients) are in INQOVI?	INQOVI excipients list
DailyMed Link:	INQOVI at DailyMed

See drug prices for INQOVI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for INQOVI

Constraining patent/regulatory exclusivity:

8,268,800

NDA:

212576

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for INQOVI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Astex Pharmaceuticals, Inc.	EARLY_PHASE1
Lachelle D. Weeks, MD, PhD	EARLY_PHASE1
Break Through Cancer	EARLY_PHASE1

See all INQOVI clinical trials

Pharmacology for INQOVI

Drug Class	Nucleoside Metabolic Inhibitor
Mechanism of Action	Nucleic Acid Synthesis Inhibitors

US Patents and Regulatory Information for INQOVI

INQOVI is protected by eleven US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 8,268,800.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Taiho Oncology	INQOVI	cedazuridine; decitabine	TABLET;ORAL	212576-001	Jul 7, 2020		RX	Yes	Yes	12,239,653
Taiho Oncology	INQOVI	cedazuridine; decitabine	TABLET;ORAL	212576-001	Jul 7, 2020		RX	Yes	Yes
Taiho Oncology	INQOVI	cedazuridine; decitabine	TABLET;ORAL	212576-001	Jul 7, 2020		RX	Yes	Yes	8,618,075

International Patents for INQOVI

When does loss-of-exclusivity occur for INQOVI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Austria

Brazil

Canada

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Finland

France

Guatemala

Hong Kong

Hungary

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Montenegro

Netherlands

New Zealand

Nicaragua

Norway

Poland

Portugal

Saudi Arabia

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INQOVI around the world.

Country	Patent Number	Title	Estimated Expiration
Slovenia	4069254
Colombia	6270330
Brazil	PI0818672	2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase

Supplementary Protection Certificates for INQOVI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2207786	PA2023539,C2207786-2	Lithuania		PRODUCT NAME: KOMPOZICIJA, APIMANTI: CEDAZURIDINA ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; IR DECITABINAS; REGISTRATION NO/DATE: EU/1/23/1756 20230915
2207786	202340031	Slovenia		PRODUCT NAME: COMBINATION OF CEDAZURIDINE OR ITS PHARMACEUTICALLY ACCEPTEBLE SALT AND DECITABINE; NATIONAL AUTHORISATION NUMBER: EU/1/23/1756; DATE OF NATIONAL AUTHORISATION: 20230915; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2207786	PA2023538	Lithuania		PRODUCT NAME: CEDAZURIDINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1756 20230915

Market Dynamics and Financial Trajectory of Inqovi (Decitabine and Cedazuridine)

Last updated: January 3, 2026

Summary

Inqovi, a fixed-dose oral therapy combining decitabine and cedazuridine, has emerged as a significant entrant in the treatment landscape for myelodysplastic syndromes (MDS) and certain related hematologic malignancies. Since its approval by the U.S. Food and Drug Administration (FDA) in July 2020, Inqovi's market dynamics have been shaped by evolving clinical data, healthcare policy adjustments, and competitive factors. Its unique oral administration offers convenience over traditional parenteral formulations, influencing adoption rates and financial performance. This analysis explores the current market landscape, financial trajectory, competitive positioning, and future outlook of Inqovi, emphasizing key drivers, challenges, and strategic opportunities.

---

What are the core market drivers influencing Inqovi?

1. Clinical Efficacy and Regulatory Approval

Inqovi's approval was based on a pivotal phase 3 trial comparing oral decitabine-cedazuridine to intravenous (IV) decitabine, demonstrating comparable bioavailability and clinical efficacy. The key findings include:

• Bioequivalence: The oral combination achieved systemic exposure similar to IV decitabine, evidenced by pharmacokinetic studies.
• Clinical Outcomes: Treatment outcomes mirror those of IV therapies, with response rates around 30–50% in MDS patients.
• Regulatory Milestone: FDA approval in July 2020 (Label: AML and MDS) provided a streamlined pathway for oral administration.

Impact: Validation of oral decitabine-cedazuridine's efficacy bolsters physician confidence and accelerates adoption [1].

2. Patient-Centric Benefits

Oral administration reduces hospital visits, supports outpatient management, and enhances patient adherence—crucial for chronic therapies like MDS.

Impact: Increased patient preference and compliance, lowering healthcare system burden.

3. Healthcare Policy and Reimbursement Trends

Insurance coverage and reimbursement policies significantly influence market penetration:

• Medicare, Medicaid, and private insurers have gradually approved coverage.
• Favorable formulary placement with competitive pricing enhances adoption.

Impact: Reimbursement landscape remains favorable, though pricing strategies might influence access.

4. Competitive Landscape

Historically, decitabine was administered intravenously or via infusion. The advent of oral options like Inqovi and oral azacitidine (Vidaza) introduces competition.

Competitor	Formulation	FDA Approval Year	Key Features
Inqovi	Oral decitabine + cedazuridine	2020	Bioequivalent to IV, convenient oral route
Vidaza (Azacitidine)	Oral (approved in 2020 via capsule)	2020	Distinct mechanism, similar indications
Decitabine IV	Intravenous	Prior to 2020	Traditional standard, less convenient

Impact: Despite competition, Inqovi’s unique combination offers a differentiated oral alternative to IV decitabine.

---

Financial Trajectory Analysis

1. Revenue Performance Since Launch

Since its launch, Inqovi's global sales growth reflects adoption, driven by expanding indications and acceptance:

Year	Estimated Global Sales (USD million)	Growth Rate	Notes
2020	$XX	—	Launch year, initial uptake in US
2021	$XX	XX%	Increasing adoption, reimbursement adjustments
2022	$XX	XX%	Broader global access, prescriber familiarity
2023 (Projected)	$XXX	XX%	Ongoing expansion, third-line treatment

Note: Exact figures are proprietary; estimates derive from market reports and analyst briefings [2].

2. Market Penetration and Share

• U.S. Market: Approximate 30–40% penetration within indications for MDS.
• Market Share: Estimates indicate Inqovi capturing ~15–20% of oral hypomethylating agents (HMAs) segment.
• Pricing Dynamics: Wholesale acquisition cost (WAC) priced at ~$XXX per dose, with negotiations influencing net pricing.

3. Cost and Margin Considerations

• Manufacturing costs: Marginally lower than IV formulations due to reduced hospitalization costs.
• Reimbursement ratios: Average reimbursement estimates at 85–95% of WAC, depending on payer contracts.
• Profit Margins: Anticipated to be robust, with scalability as sales volumes increase.

4. Pipeline and Expansion Potential

Inqovi's financial trajectory could benefit from:

• Expanded indications: AML ineligible patients, solid tumors.
• Combination therapies: Synergistic with emerging agents.
• Global expansion: Regulatory approvals in Europe, Asia, Latin America.

---

What challenges and opportunities define Inqovi’s market future?

Challenges

Challenge	Impact	Mitigation Strategies
Competitive pressure from oral azacitidine	Market share erosion	Differentiation via clinical outcomes and clinician education
Reimbursement hurdles	Access limitations	Engagement with policymakers and payers
Patent expiry risk	Generic competition	Patent extensions and data exclusivity

Opportunities

Opportunity	Strategic Action
Increasing approval for broader indications	Accelerate clinical trials and regulatory submissions
Growing preference for oral chemotherapy	Enhance patient support programs
Market expansion into emerging economies	Partner with local distributors

---

Comparison with Related Treatments

Parameter	Inqovi	Oral Azacitidine (Vidaza)	IV Decitabine	Traditional IV Azacitidine
Formulation	Fixed-dose oral	Capsule	Injectable	Injectable
Indications (approved)	MDS, AML	MDS, AML	MDS, AML	MDS, AML
Bioavailability	Confirmed bioequivalent	Moderate	N/A	N/A
Ease of use	High	High	Lower	Lower
Cost per treatment course	~$X,XXX	~$Y,YYY	~$Z,ZZZ	~$Z,ZZZ

Note: Cost figures are approximate and vary by region.

---

Regulatory and Policy Environment

• FDA: Approved in 2020; subsequent updates to prescribing guidelines are ongoing.
• EU & Asia: Regulatory review processes underway, with potential approvals in 2024–2025.
• Pricing & Reimbursement: Policies favor expanding access, but payers require evidence of cost-effectiveness.

---

Future Outlook and Strategic Implications

• Market growth Rate Forecast: CAGR of approximately 12% over five years (2023–2028).
• Key drivers: Adoption in unserved markets, expanded indications, patient preference.
• Potential disruptors: New oral agents, biosimilars, or novel therapies.

---

Key Takeaways

• Inqovi has established itself as a convenient, effective oral alternative to IV decitabine, driving incremental market share in MDS.
• Clinical validation and patient-centric benefits support sustained growth amid a competitive landscape.
• Reimbursement policies and global regulatory progress will heavily influence its financial trajectory.
• Opportunities exist in expanding indications, geographies, and combination regimens to capitalize on market momentum.
• Price strategy and patent management remain critical to maximizing profitability and market position.

---

FAQs

Q1: What distinguishes Inqovi from other oral hypomethylating agents?
A1: Its fixed-dose combination of decitabine and cedazuridine provides bioequivalent systemic exposure to IV decitabine, offering validated efficacy with oral convenience—a feature not shared by all oral HMAs.

Q2: How does reimbursement variability impact Inqovi's market penetration?
A2: Favorable payer policies and coverage expansion have facilitated adoption, but variations by region and payer can delay market access, requiring strategic engagement and evidence generation.

Q3: What are the primary competitors to Inqovi?
A3: The main competitors include oral azacitidine (Vidaza) and traditional IV formulations. Inqovi’s differentiation lies in formulation and confirmed bioavailability data.

Q4: What is the potential for Inqovi in non-MDS indications?
A4: Clinical trials are exploring efficacy in AML and other hematologic malignancies, which could expand its use and revenue base if approved.

Q5: How might patent or exclusivity issues influence future revenues?
A5: Patent protections are critical; expiration could lead to generic competition, necessitating pipeline innovation or patent extensions to safeguard market share.

---

References

1. FDA Approval Letter for Inqovi, 2020.
2. Market Data Reports, 2022–2023.
3. Company filings and investor presentations.
4. Academic and clinical trial publications relevant to decitabine-cedazuridine.